Stocks
Kite Therapeutics IncKITE
YHDHealthcareBiotechnology
A clinical-stage biopharmaceutical company focused on developing targeted cancer therapies, particularly for patients with genetically defined tumors. Its lead programs include investigational agents targeting oncogenic drivers, and it has drawn investor attention for its early-stage data and partnerships in precision oncology.
Congressional Interest in Kite Therapeutics Inc (KITE)
1 member of Congress has disclosed 1 trade in Kite Therapeutics Inc (KITE), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading KITE?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-11-23 | James Comer | buy | $1K-$15K |